Pörssitiedote24.5.2025 klo 10.40Lipidor announces today negative results from the company's Phase III clinical study of AKP02G2 for psoriasis
Lehdistötiedote19.5.2025 klo 6.30Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2
Lehdistötiedote21.1.2025 klo 7.00Lipidor announces half of patients enrolled in ongoing Phase III study
Lehdistötiedote20.11.2024 klo 7.00Lipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025"
Lehdistötiedote24.9.2024 klo 16.30Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis
Lehdistötiedote20.8.2024 klo 11.50Lipidor announces that clinical trial material for psoriasis candidate AKP02G2 has been released according to plan
Pörssitiedote1.7.2024 klo 6.15Lipidor resolves on a directed issue of shares to underwriters in connection with the completion of the rights issue
Pörssitiedote25.6.2024 klo 19.57Lipidor's rights issue and share capital reduction are registered – conversion of BTU into shares and warrants